Molecular Biology Reports

, Volume 39, Issue 6, pp 6915–6922

Influence of MIF, CD40, and CD226 polymorphisms on risk of rheumatoid arthritis

  • Ruiping Liu
  • Nanwei Xu
  • Xinxiang Wang
  • Li Shen
  • Gongyin Zhao
  • Hui Zhang
  • Weimin Fan
Article

Abstract

Macrophage migration inhibitory factor (MIF) is a key pro-inflammatory mediator. It plays an important role part in the pathogenesis of several inflammatory and immune diseases. A functional single nucleotide polymorphism (SNP) of MIF −173 G/C is known to influence MIF promoter activity in T lymphoblast cell lines and is associated with a higher serum MIF level. The CD40 is also crucial for some relevant functions of the immune system and may be related to rheumatoid arthritis (RA). And CD226 is an important cell-surface receptor molecule involved in the adhesion and activation of T-cell. We hypothesized that these polymorphisms may contribute to RA susceptibility. We studied MIF −173 G/C, CD40, and CD226 gene polymorphisms in 214 patients with RA and 478 controls in a Chinese population. Genotyping was done by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). When the MIF −173 GG homozygote genotype was used as the reference group, the CC genotype was associated with a significantly increased risk for RA. In the recessive model, when the MIF −173 GG/GC genotypes were used as the reference group, the CC homozygote genotype was associated with a significant 1.56-fold increased susceptibility to RA. None of the CD40 rs1883832 C/T and CD226 rs763361 C/T polymorphisms achieved a significant difference in genotype distributions between cases and controls. In the stratification analyzes, a significantly increased risk for RA associated with the MIF −173 CC genotype was evident among CRP-negative patients compared with the MIF −173 GG/GC genotype. For the CD40 rs1883832 C/T variant, the risk effects of CD40 rs1883832 TT versus CD40 rs1883832 CC/CT were significant in men. These findings suggested that the functional SNP MIF −173 G/C variant allele was associated with the development of RA. However, CD40 and CD226 gene polymorphisms may not be associated with RA susceptibility. Due to the limitation of sample size, this study should be considered preliminary.

Keywords

MIF CD40 CD226 Polymorphisms Rheumatoid arthritis Molecular epidemiology 

Abbreviations

CI

Confidential interval

MIF

Macrophage migration inhibitory factor

LD

Linkage disequilibrium

OR

Odds ratio

SNP

Single nucleotide polymorphism

References

  1. 1.
    Iguchi T, Ziff M (1986) Electron microscopic study of rheumatoid synovial vasculature. Intimate relationship between tall endothelium and lymphoid aggregation. J Clin Invest 77:355–361PubMedCrossRefGoogle Scholar
  2. 2.
    FitzGerald O, Soden M, Yanni G, Robinson R, Bresnihan B (1991) Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 50:792–796PubMedCrossRefGoogle Scholar
  3. 3.
    Markenson JA (1991) Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum 21:4–12PubMedCrossRefGoogle Scholar
  4. 4.
    MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–37PubMedCrossRefGoogle Scholar
  5. 5.
    Hasstedt SJ, Clegg DO, Ingles L, Ward RH (1994) HLA-linked rheumatoid arthritis. Am J Hum Genet 55:738–746PubMedGoogle Scholar
  6. 6.
    Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TR, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PL, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth BP, Wijmenga C, Karlson EW, Toes RE, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–514PubMedCrossRefGoogle Scholar
  7. 7.
    Budarf M, McDonald T, Sellinger B, Kozak C, Graham C, Wistow G (1997) Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. Genomics 39:235–236PubMedCrossRefGoogle Scholar
  8. 8.
    Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 365:756–759PubMedCrossRefGoogle Scholar
  9. 9.
    Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895–1902PubMedCrossRefGoogle Scholar
  10. 10.
    Kudrin A, Ray D (2008) Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol 86:232–238PubMedCrossRefGoogle Scholar
  11. 11.
    Santos L, Hall P, Metz C, Bucala R, Morand EF (2001) Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 123:309–314PubMedCrossRefGoogle Scholar
  12. 12.
    Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of pro-inflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRefGoogle Scholar
  13. 13.
    Meazza C, Travaglino P, Pignatti P, Magni-Manzoni S, Ravelli A, Martini A, De Benedetti F (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:232–237PubMedCrossRefGoogle Scholar
  14. 14.
    Onodera S, Tanji H, Suzuki K, Kaneda K, Mizue Y, Sagawa A, Nishihira J (1999) High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11:163–167PubMedCrossRefGoogle Scholar
  15. 15.
    Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R (2002) A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176PubMedCrossRefGoogle Scholar
  16. 16.
    Renner P, Roger T, Calandra T (2005) Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41(Suppl 7):S513–S519PubMedCrossRefGoogle Scholar
  17. 17.
    Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029PubMedCrossRefGoogle Scholar
  18. 18.
    Chang YY, Greinix HT, Dickinson AM, Wolff D, Jackson GH, Andreesen R, Holler E, Hildebrandt GC (2009) G to C transition at position −173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation. Cytokine 48:218–225PubMedCrossRefGoogle Scholar
  19. 19.
    Martinez A, Orozco G, Varade J, Sanchez Lopez M, Pascual D, Balsa A, Garcia A, de la Concha EG, Fernandez-Gutierrez B, Martin J, Urcelay E (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747PubMedCrossRefGoogle Scholar
  20. 20.
    Donn RP, Shelley E, Ollier WE, Thomson W (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785PubMedCrossRefGoogle Scholar
  21. 21.
    Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coblyn J, Cui J, Tak PP, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Criswell LA, Amos CI, Seldin MF, Kastner DL, Ardlie KG, Alfredsson L, Costenbader KH, Altshuler D, Huizinga TW, Shadick NA, Weinblatt ME, de Vries N, Worthington J, Seielstad M, Toes RE, Karlson EW, Begovich AB, Klareskog L, Gregersen PK, Daly MJ, Plenge RM (2008) Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 40:1216–1223PubMedCrossRefGoogle Scholar
  22. 22.
    Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, Stevens HE, Walker NM, Healy B, Howson JM, Maisuria M, Duley S, Coleman G, Gough SC, Worthington J, Kuchroo VK, Wicker LS, Todd JA (2009) CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 10:5–10PubMedCrossRefGoogle Scholar
  23. 23.
    Mysliwiec J, Oklota M, Nikolajuk A, Waligorski D, Gorska M (2007) Serum CD40/CD40L system in Graves’ disease and Hashimoto’s thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response. Immunol Invest 36:247–257PubMedCrossRefGoogle Scholar
  24. 24.
    Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677PubMedCrossRefGoogle Scholar
  25. 25.
    Mukai T, Hiromatsu Y, Fukutani T, Ichimura M, Kaku H, Miyake I, Yamada K (2005) A C/T polymorphism in the 5′ untranslated region of the CD40 gene is associated with later onset of Graves’ disease in Japanese. Endocr J 52:471–477PubMedCrossRefGoogle Scholar
  26. 26.
    Du Y, Shen LX, Yu LK, Song Y, Zhu JF, Du R (2011) The CD226 gene in susceptibility of rheumatoid arthritis in the Chinese Han population. Rheumatol IntGoogle Scholar
  27. 27.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  28. 28.
    Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M (2008) Highly multiplexed genotyping of thiopurine S-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 54:1637–1647PubMedCrossRefGoogle Scholar
  29. 29.
    Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of toll-like receptor 4. Nature 414:920–924PubMedCrossRefGoogle Scholar
  30. 30.
    Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRefGoogle Scholar
  31. 31.
    Donn RP, Ray DW (2004) Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 182:1–9PubMedCrossRefGoogle Scholar
  32. 32.
    De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, Lunt M, Thomson W, Ravelli A, Donn R, Martini A (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48:1398–1407PubMedCrossRefGoogle Scholar
  33. 33.
    Xue Y, Xu H, Rong L, Lu Q, Li J, Tong N, Wang M, Zhang Z, Fang Y (2010) The MIF −173 G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res 34:1282–1286PubMedCrossRefGoogle Scholar
  34. 34.
    Ziino O, D’Urbano LE, De Benedetti F, Conter V, Barisone E, De Rossi G, Basso G, Arico M (2005) The MIF −173 G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia 19:2346–2347PubMedCrossRefGoogle Scholar
  35. 35.
    Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE, Thomson W, Ray D (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409PubMedCrossRefGoogle Scholar
  36. 36.
    Petrenko O, Moll UM (2005) Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 17:225–236PubMedCrossRefGoogle Scholar
  37. 37.
    Sadki K, Lamsyah H, Rueda B, Akil E, Sadak A, Martin J, El Aouad R (2010) Analysis of MIF, FCGR2A, and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J Genet Genomics 37:257–264PubMedCrossRefGoogle Scholar
  38. 38.
    Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, Stamp L, Steer S, Merriman TR, Vyse TJ (2010) A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med 7:e1000341PubMedCrossRefGoogle Scholar
  39. 39.
    Jacobson EM, Concepcion E, Oashi T, Tomer Y (2005) A Graves’ disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 146:2684–2691PubMedCrossRefGoogle Scholar
  40. 40.
    Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Diaz-Gallo LM, Gomez-Garcia M, Lopez-Nevot MA, Rodrigo L, Nieto A, Cardena C, Alcain G, Diaz-Rubio M, de la Concha EG, Fernandez O, Arroyo R, Martin J, Urcelay E (2010) CD40: novel association with Crohn’s disease and replication in multiple sclerosis susceptibility. PLoS One 5:e11520PubMedCrossRefGoogle Scholar
  41. 41.
    Tripathi G, Borkar M, Akhter A, Sankhwar SN, Sharma RK, Agrawal S (2010) Association of pro-inflammatory cytokines with end stage renal disease. Cytokine 50:278–283PubMedCrossRefGoogle Scholar
  42. 42.
    Vivarelli M, D’Urbano LE, Stringini G, Ghiggeri GM, Caridi G, Donn R, Tozzi A, Emma F, De Benedetti F (2008) Association of the macrophage migration inhibitory factor −173*C allele with childhood nephrotic syndrome. Pediatr Nephrol 23:743–748PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Ruiping Liu
    • 1
    • 2
  • Nanwei Xu
    • 1
  • Xinxiang Wang
    • 1
  • Li Shen
    • 3
  • Gongyin Zhao
    • 1
  • Hui Zhang
    • 1
  • Weimin Fan
    • 4
  1. 1.Department of OrthopedicsThe Affiliated Hospital of Nanjing Medical University, Changzhou Second People’s HospitalChangzhouChina
  2. 2.Central LaboratoryThe Affiliated Hospital of Nanjing Medical University, Changzhou Second People’s HospitalChangzhouChina
  3. 3.Changzhou First People’s HospitalChangzhouChina
  4. 4.Department of OrthopedicsThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina

Personalised recommendations